Cargando…
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
SIMPLE SUMMARY: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with systemic treatments such as sorafenib. Hepatic arterial infusion chemotherapy (HAIC) is the treatment using an indwelling catheter port system. The regimen of HAIC used in the study is New FP which is co...
Autores principales: | Iwamoto, Hideki, Niizeki, Takashi, Nagamatsu, Hiroaki, Ueshima, Kazuomi, Nomura, Takako, Kuzuya, Teiji, Kasai, Kazuhiro, Kooka, Yohei, Hiraoka, Atsushi, Sugimoto, Rie, Yonezawa, Takehiro, Ishihara, Akio, Deguchi, Akihiro, Arai, Hirotaka, Shimose, Shigeo, Shirono, Tomotake, Nakano, Masahito, Okamura, Shusuke, Noda, Yu, Kamachi, Naoki, Sakai, Miwa, Suzuki, Hiroyuki, Aino, Hajime, Matsukuma, Norito, Matsugaki, Satoru, Ogata, Kei, Yano, Yoichi, Ueno, Takato, Kajiwara, Masahiko, Itano, Satoshi, Fukuizumi, Kunitaka, Kawano, Hiroshi, Noguchi, Kazunori, Tanaka, Masatoshi, Yamaguchi, Taizo, Kuromatsu, Ryoko, Kawaguchi, Atsushi, Koga, Hironori, Torimura, Takuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915251/ https://www.ncbi.nlm.nih.gov/pubmed/33562793 http://dx.doi.org/10.3390/cancers13040646 |
Ejemplares similares
-
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021) -
Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study
por: Shirono, Tomotake, et al.
Publicado: (2021) -
First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shimose, Shigeo, et al.
Publicado: (2021) -
Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020) -
Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound
por: Kamachi, Naoki, et al.
Publicado: (2021)